Ontology highlight
ABSTRACT:
SUBMITTER: Li S
PROVIDER: S-EPMC6888008 | biostudies-literature | 2019 Nov
REPOSITORIES: biostudies-literature
Li Simeng S Tarlac Volga V Hamilton Justin R JR
International journal of molecular sciences 20191111 22
Protease-activated receptors (PARs) are a family of four GPCRs with a variety of cellular functions, yet the only advanced clinical endeavours to target these receptors for therapeutic gain to date relates to the impairment of platelet function for anti-thrombotic therapy. The only approved PAR antagonist is the PAR1 inhibitor, vorapaxar-the sole anti-platelet drug against a new target approved in the past 20 years. However, there are two PARs on human platelets, PAR1 and PAR4, and more recent e ...[more]